Search

Your search keyword '"Tomcsányi, János"' showing total 24 results
Start Over Author "Tomcsányi, János" Search Limiters Full Text
24 results on '"Tomcsányi, János"'

2. Chronic renal failure in patients hospitalized for heart failure

Author

Tomcsányi János, Arányi Péter, Kántor Zita, and Csizmadia Zoltán

Subjects
chronic kidney disease, heart failure, sglt2 inhibitors, hospitalization, Specialties of internal medicine, RC581-951
Abstract

Aim of the study: Assessment of the incidence of real and diagnosed chronic renal failure in patients hospitalized for heart failure, assessment of factors affecting the recording of the diagnosis. Methods and patients: Retrospective analysis in patients treated for heart failure over a period of 6 months in a cardiology department. The diagnosis of heart failure was based on symptoms, elevated NT-proBNP level and echocardiographic examination. Only an eGFR below 60 ml/min/f was taken for the CKD diagnosis. Results: 61% of hospitalized heart failure patients had CKD, but only 31.8% of CKD patients were diagnosed. The appearance of CKD in the diagnosis was most influenced by the severity of eGFR, less by the type of heart failure and not at all by diabetes as a comorbidity. Conclusion: Chronic kidney disease is a common but underdiagnosed companion of heart failure that needs more attention in the future due to the beneficial effects of SGLT2 inhibitors.

Published
2024
Full Text
View/download PDF

7. Gasztroenterológiai-kardiológiai multidiszciplináris konszenzus a hatékony gasztroprotekció szükségességéről antitrombotikus kezelés alkalmazásakor : A Magyar Gasztroenterológiai Társaság és a Magyar Kardiológusok Társaságának közös állásfoglalása

Author

Herszényi, László, primary, Aradi, Dániel, additional, Békássy, Szabolcs, additional, Járai, Zoltán, additional, Juhász, Márk, additional, Kiss, Róbert Gábor, additional, Kolossváry, Endre, additional, Nárdai, Sándor, additional, Simonyi, Gábor, additional, Szőnyi, Mihály, additional, Tomcsányi, János, additional, Torzsa, Péter, additional, Tulassay, Zsolt, additional, Vincze, Áron, additional, and becker, Dávid, additional

Published
2023
Full Text
View/download PDF

9. Az aritmogén cardiomyopathia szokatlan megjelenési formái : Amikor a genetika segít

Author

Dohy, Zsófia, primary, Fekete, Bálint, additional, Csonka, Katalin, additional, Nagy, Beáta, additional, Fintha, Attila, additional, Szabó, Liliána, additional, Juhász, Vencel, additional, Czibor, Sándor, additional, Balla, Dorottya, additional, Tomcsányi, János, additional, Karlócai, Kristóf, additional, Matolcsy, András, additional, Merkely, Béla, additional, Bödör, Csaba, additional, and Vágó, Hajnalka, additional

Published
2022
Full Text
View/download PDF

10. Assessment of omecamtiv mecarbil for the treatment of patients with severe heart failure: a post hoc analysis of data from the GALACTIC-HF randomized clinical trial

Author

Felker, G. Michael, Solomon, Scott D., Claggett, Brian, Díaz, Rafael, McMurray, John J.V., Metra, Marco, Anad, Inder, Crespo-Leiro, María Generosa, Dahlström, Ulf, Goncalvesova, Eva, Howlett, Jonathan G., MacDonald, Peter, Parkhomenko, Alexander, Tomcsányi, János, Abbasi, Siddique A., Heitner, Stephen B., Hucko, Thomas, Kupfer, Stuart, Malik, Fady I., Teerlink, John R., Felker, G. Michael, Solomon, Scott D., Claggett, Brian, Díaz, Rafael, McMurray, John J.V., Metra, Marco, Anad, Inder, Crespo-Leiro, María Generosa, Dahlström, Ulf, Goncalvesova, Eva, Howlett, Jonathan G., MacDonald, Peter, Parkhomenko, Alexander, Tomcsányi, János, Abbasi, Siddique A., Heitner, Stephen B., Hucko, Thomas, Kupfer, Stuart, Malik, Fady I., and Teerlink, John R.

Abstract

[Abstract] Importance: Heart failure with reduced ejection fraction is a progressive clinical syndrome, and many patients' condition worsen over time despite treatment. Patients with more severe disease are often intolerant of available medical therapies. Objective: To evaluate the efficacy and safety of omecamtiv mecarbil for the treatment of patients with severe heart failure (HF) enrolled in the Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure (GALACTIC-HF) randomized clinical trial. Design, setting, and participants: The GALACTIC-HF study was a global double-blind, placebo-controlled phase 3 randomized clinical trial that was conducted at multiple centers between January 2017 and August 2020. A total of 8232 patients with symptomatic HF (defined as New York Heart Association symptom class II-IV) and left ventricular ejection fraction of 35% or less were randomized to receive omecamtiv mecarbil or placebo and followed up for a median of 21.8 months (range, 15.4-28.6 months). The current post hoc analysis evaluated the efficacy and safety of omecamtiv mecarbil therapy among patients classified as having severe HF compared with patients without severe HF. Severe HF was defined as the presence of all of the following criteria: New York Heart Association symptom class III to IV, left ventricular ejection fraction of 30% or less, and hospitalization for HF within the previous 6 months. Interventions: Participants were randomized at a 1:1 ratio to receive either omecamtiv mecarbil or placebo. Main outcomes and measures: The primary end point was time to first HF event or cardiovascular (CV) death. Secondary end points included time to CV death and safety and tolerability. Results: Among 8232 patients enrolled in the GALACTIC-HF clinical trial, 2258 patients (27.4%; mean [SD] age, 64.5 [11.6] years; 1781 men [78.9%]) met the specified criteria for severe HF. Of those, 1106 patients were randomized to the omecamtiv mec

Published
2021

20. TCT-804 Comparative Validation of the ALPHA Score, a Novel Risk Model Including Vascular Access Site for Predicting 30-Day Mortality in Patients Treated With Primary PCI

Author

Hizoh, Istvan, Banhegyi, Gyongyver, Domokos, Dominika, Major, Laszlo, Andrassy, Peter, Andreka, Peter, Becker, Dávid, Buttl, Andrea, Cziraki, Attila, Dezsi, Csaba Andras, Edes, Istvan, Forster, Tamas, Herczeg, Bela, Janosi, Andras, Katona, Andras, Kiss, Robert, Koszegi, Zsolt, Lupkovics, Geza, Nagy, Gergely, Nagy, Lajos, Noori, Ebrahim, Tomcsanyi, Janos, Veress, Gábor, Ruzsa, Zoltan, and Merkely, Bela

Published
2018
Full Text
View/download PDF

21. Dronedarone in High-Risk Permanent Atrial Fibrillation

Author

Connolly, Stuart J, Camm, A John, Halperin, Jonathan L, Joyner, Campbell, Alings, Marco, Amerena, John, Atar, Dan, Avezum, Alvaro, Blomström, Per, Borggrefe, Martin, Budaj, Andrzej, Chen, Shih-Ann, Ching, Chi Keong, Commerford, Patrick, Dans, Antonio, Davy, Jean-Marc, Delacrétaz, Etienne, Di Pasquale, Giuseppe, Diaz, Rafael, Dorian, Paul, Flaker, Greg, Golitsyn, Sergey, Gonzalez-Hermosillo, Antonio, Granger, Christopher B, Heidbüchel, Hein, Kautzner, Josef, Kim, June Soo, Lanas, Fernando, Lewis, Basil S, Merino, Jose L, Morillo, Carlos, Murin, Jan, Narasimhan, Calambur, Paolasso, Ernesto, Parkhomenko, Alexander, Peters, Nicholas S, Sim, Kui-Hian, Stiles, Martin K, Tanomsup, Supachai, Toivonen, Lauri, Tomcsányi, János, Torp-Pedersen, Christian, Tse, Hung-Fat, Vardas, Panos, Vinereanu, Dragos, Xavier, Denis, Zhu, Jun, Zhu, Jun-Ren, Baret-Cormel, Lydie, Weinling, Estelle, Staiger, Christoph, Yusuf, Salim, Chrolavicius, Susan, Afzal, Rizwan, Hohnloser, Stefan H, Connolly, Stuart J, Camm, A John, Halperin, Jonathan L, Joyner, Campbell, Alings, Marco, Amerena, John, Atar, Dan, Avezum, Alvaro, Blomström, Per, Borggrefe, Martin, Budaj, Andrzej, Chen, Shih-Ann, Ching, Chi Keong, Commerford, Patrick, Dans, Antonio, Davy, Jean-Marc, Delacrétaz, Etienne, Di Pasquale, Giuseppe, Diaz, Rafael, Dorian, Paul, Flaker, Greg, Golitsyn, Sergey, Gonzalez-Hermosillo, Antonio, Granger, Christopher B, Heidbüchel, Hein, Kautzner, Josef, Kim, June Soo, Lanas, Fernando, Lewis, Basil S, Merino, Jose L, Morillo, Carlos, Murin, Jan, Narasimhan, Calambur, Paolasso, Ernesto, Parkhomenko, Alexander, Peters, Nicholas S, Sim, Kui-Hian, Stiles, Martin K, Tanomsup, Supachai, Toivonen, Lauri, Tomcsányi, János, Torp-Pedersen, Christian, Tse, Hung-Fat, Vardas, Panos, Vinereanu, Dragos, Xavier, Denis, Zhu, Jun, Zhu, Jun-Ren, Baret-Cormel, Lydie, Weinling, Estelle, Staiger, Christoph, Yusuf, Salim, Chrolavicius, Susan, Afzal, Rizwan, and Hohnloser, Stefan H

Abstract

Background Dronedarone restores sinus rhythm and reduces hospitalization or death in intermittent atrial fibrillation. It also lowers heart rate and blood pressure and has antiadrenergic and potential ventricular anti-arrhythmic effects. We hypothesized that dronedarone would reduce major vascular events in high-risk permanent atrial fibrillation. Methods We assigned patients who were at least 65 years of age with at least a 6-month history of permanent atrial fibrillation and risk factors for major vascular events to receive dronedarone or placebo. The first coprimary outcome was stroke, myocardial infarction, systemic embolism, or death from cardiovascular causes. The second coprimary outcome was unplanned hospitalization for a cardiovascular cause or death. Results After the enrollment of 3236 patients, the study was stopped for safety reasons. The first coprimary outcome occurred in 43 patients receiving dronedarone and 19 receiving placebo (hazard ratio, 2.29; 95% confidence interval [CI], 1.34 to 3.94; P=0.002). There were 21 deaths from cardiovascular causes in the dronedarone group and 10 in the placebo group (hazard ratio, 2.11; 95% CI, 1.00 to 4.49; P=0.046), including death from arrhythmia in 13 patients and 4 patients, respectively (hazard ratio, 3.26; 95% CI, 1.06 to 10.00; P=0.03). Stroke occurred in 23 patients in the dronedarone group and 10 in the placebo group (hazard ratio, 2.32; 95% CI, 1.11 to 4.88; P=0.02). Hospitalization for heart failure occurred in 43 patients in the dronedarone group and 24 in the placebo group (hazard ratio, 1.81; 95% CI, 1.10 to 2.99; P=0.02). Conclusions Dronedarone increased rates of heart failure, stroke, and death from cardiovascular causes in patients with permanent atrial fibrillation who were at risk for major vascular events. Our data show that this drug should not be used in such patients.

Published
2011
Full Text
View/download PDF

22. Dronedarone in high-risk permanent atrial fibrillation.

Author

UCL - (MGD) Service de cardiologie, Connolly, Stuart J, Camm, A John, Halperin, Jonathan L, Joyner, Campbell, Alings, Marco, Amerena, John, Atar, Dan, Avezum, Álvaro, Blomström, Per, Borggrefe, Martin, Budaj, Andrzej, Chen, Shih-Ann, Ching, Chi Keong, Commerford, Patrick, Dans, Antonio, Davy, Jean-Marc, Delacrétaz, Etienne, Di Pasquale, Giuseppe, Diaz, Rafael, Dorian, Paul, Flaker, Greg, Golitsyn, Sergey, Gonzalez-Hermosillo, Antonio, Granger, Christopher B, Heidbüchel, Hein, Kautzner, Josef, Kim, June Soo, Lanas, Fernando, Lewis, Basil S, Merino, Jose L, Morillo, Carlos, Murin, Jan, Narasimhan, Calambur, Paolasso, Ernesto, Parkhomenko, Alexander, Peters, Nicholas S, Sim, Kui-Hian, Stiles, Martin K, Tanomsup, Supachai, Toivonen, Lauri, Tomcsányi, János, Torp-Pedersen, Christian, Tse, Hung-Fat, Vardas, Panos, Vinereanu, Dragos, Xavier, Denis, Zhu, Jun, Zhu, Jun-Ren, Baret-Cormel, Lydie, Weinling, Estelle, Staiger, Christoph, Yusuf, Salim, Chrolavicius, Susan, Afzal, Rizwan, Hohnloser, Stefan H, PALLAS Investigators, Deceuninck, Olivier, UCL - (MGD) Service de cardiologie, Connolly, Stuart J, Camm, A John, Halperin, Jonathan L, Joyner, Campbell, Alings, Marco, Amerena, John, Atar, Dan, Avezum, Álvaro, Blomström, Per, Borggrefe, Martin, Budaj, Andrzej, Chen, Shih-Ann, Ching, Chi Keong, Commerford, Patrick, Dans, Antonio, Davy, Jean-Marc, Delacrétaz, Etienne, Di Pasquale, Giuseppe, Diaz, Rafael, Dorian, Paul, Flaker, Greg, Golitsyn, Sergey, Gonzalez-Hermosillo, Antonio, Granger, Christopher B, Heidbüchel, Hein, Kautzner, Josef, Kim, June Soo, Lanas, Fernando, Lewis, Basil S, Merino, Jose L, Morillo, Carlos, Murin, Jan, Narasimhan, Calambur, Paolasso, Ernesto, Parkhomenko, Alexander, Peters, Nicholas S, Sim, Kui-Hian, Stiles, Martin K, Tanomsup, Supachai, Toivonen, Lauri, Tomcsányi, János, Torp-Pedersen, Christian, Tse, Hung-Fat, Vardas, Panos, Vinereanu, Dragos, Xavier, Denis, Zhu, Jun, Zhu, Jun-Ren, Baret-Cormel, Lydie, Weinling, Estelle, Staiger, Christoph, Yusuf, Salim, Chrolavicius, Susan, Afzal, Rizwan, Hohnloser, Stefan H, PALLAS Investigators, and Deceuninck, Olivier

Abstract

Dronedarone increased rates of heart failure, stroke, and death from cardiovascular causes in patients with permanent atrial fibrillation who were at risk for major vascular events. Our data show that this drug should not be used in such patients. (Funded by Sanofi-Aventis; PALLAS ClinicalTrials.gov number, NCT01151137.).

Published
2011

Catalog

Books, media, physical & digital resources
See catalog results